Respiratory Motion announced today its plans to launch the newest version of its ExSpiron 1Xi Minute Ventilation (MV) Monitor at the ASA in Boston, October 21-25 following recent FDA clearance.
- The FDA has cleared the newest version of the non-invasive ExSpiron Minute Ventilation Monitor which does not require calibration.
|
| [18-October-2017] |
| WALTHAM, Mass., Oct. 18, 2017 /PRNewswire/ -- Respiratory Motion, Inc. , announced today its plans to launch the newest version of its ExSpiron 1Xi Minute Ventilation (MV) Monitor at the American Society of Anesthesiologists (ASA) in Boston, October 21-25 following recent FDA 510(k) clearance. This new ExSpiron requires no calibration, which greatly expands its range of use. Physicians, nurses, respiratory therapists, EMT’s and first responders can now easily assess and measure a patients breathing in seconds. http://photos.prnewswire.com/prnvar/20160320/346060LOGO Respiratory failure is the third most prevalent cause of death in the US. Opioid-induced respiratory depression is increasingly common, not only in the hospital setting but in the community as well. While the opioid epidemic needs to be addressed at multiple levels, the ExSpiron now provides caregivers a convenient method to quickly, accurately and non-invasively assess breathing in a variety of settings. Despite the focus on the dangers of recreational use, opioids continue to be important in delivering pain relief during and after surgery and for certain categories of chronic pain. Similar to alcohol, each individual has a specific sensitivity (or tolerance) to opioids. Finding the right dose to manage pain without causing respiratory depression is challenging. In an era where clinicians and hospitals are concerned with both patient safety and patient satisfaction, safe pain control has become critical. Respiratory Motion’s ExSpiron is the first and only non-invasive monitor that can quickly and accurately assess a person’s breathing. The ExSpiron measures Minute Ventilation (MV), Tidal Volume and Respiratory Rate. MV is the fundamental unit of breathing -- the amount of air that moves into and out of the lungs every minute. ExSpiron MV measurements have been shown to be superior to indirect measurements of breathing in numerous peer reviewed studies. These indirect measures are slow to respond when breathing drops to a dangerous level, whereas the ExSpiron responds first and most reliably to changes in breathing. Addressing early changes in respiratory status can prevent further deterioration leading to respiratory failure or arrest. The new ExSpiron can be used easily and effectively in all areas of the hospital, as well as in the field, providing immediate, quantitative measurements of breathing (MV) when and where they are most needed. With rapid delivery of previously unavailable information about a patient’s breathing, the new ExSpiron can be lifesaving. The newest ExSpiron Minute Ventilation Monitor will be displayed at the ASA Conference, October 21st - 23rd, 2017, at the Boston Convention Center, Exhibit #3623. The broad utility of the newest ExSpiron will be supported by five presentations over the course of the 5 day conference:
About Respiratory Motion, Inc. Respiratory Motion, Inc. is the global leader in innovative Minute Ventilation Monitoring, useful across a wide variety of patient populations and environments. Our mission is to improve the quality and experience of care and reduce costs by providing continuous, accurate, real-time, non-invasive respiratory monitoring wherever care is delivered. www.respiratorymotion.com View original content:http://www.prnewswire.com/news-releases/respiratory-motion-inc-is-excited-to-announce-the-launch-of-the-latest-exspiron-1xi-respiratory-monitor-300538455.html SOURCE Respiratory Motion, Inc. |
